EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Temporal Trends in Patient Characteristics, Anticoagulation Treatment Quality, and Clinical Outcomes of Individuals Receiving Vitamin K Antagonists in the Netherlands (2014 Until–2022)

Gilda D Zielinski iD, Qingui Chen iD, Marieke J H A Kruip, Frederikus A Klok iD, Suzanne C Cannegieter iD, Nienke van Rein iD

Pharmacoepidemiology and Drug Safety · 2026

DOI: 10.1002/pds.70494 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2026. Verfasst von Gilda D Zielinski und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands. Hauptthemen laut MEDLINE: Anticoagulants, Vitamin K, Hemorrhage, Thromboembolism. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To describe temporal trends in the clinical landscape of vitamin K antagonist (VKA) treatment in the Netherlands, after the introduction of a lower international normalized ratio (INR) target range in 2016 and direct oral anticoagulants.

Methods

Data from 17 Dutch anticoagulation clinics between 2014 and 2022 were individually linked to nationwide healthcare data. Prevalent VKA users were identified on January 1 of each year, forming nine annual cohorts. We assessed baseline patient characteristics, anticoagulation treatment quality (using time in/above/below therapeutic range [TTR/ATR/BTR]), and annual odds ratios of major bleeding and thromboembolism for each cohort.

Results

The number of patients treated with VKAs increased from 101 090 in 2014 to 121 916 in 2017, followed by a decline to 73 649 in 2022. Over time, cohorts were characterized by increasing age and a higher prevalence of comorbidities, with a doubling of kidney disease. After the introduction of the lower INR target range, mean BTR decreased (~30% in 2014 to ~15% in 2022), while mean TTR increased (~54% in 2014 to ~67% in 2022), with stable mean ATR. Across calendar years, the 1‐year odds ratio of major bleeding decreased from 1.71% (95% CI 1.63–1.79) in 2014 to 1.52% (95% CI 1.44–1.61) in 2022, whereas the odds ratio of ischemic stroke/transient ischemic attack/systemic thromboembolism increased from 1.14% (95% CI 1.08–1.21) in 2014 to 1.32% (95% CI 1.24–1.40) in 2022. The 1‐year odds ratio of mortality increased from 5.09 (95% CI 4.95–5.22) to 8.55 (95% CI 8.35–8.75), with an OR of 1.74 (95% CI 1.68–1.81).

Conclusions

VKA users declined between 2014 and 2022. The remaining patients using VKA became older and more comorbid. During this period, INR target ranges were lowered, while temporal changes were observed with decreasing odds ratio of major bleeding and increasing odds ratio of thromboembolism and mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticoagulantsVitamin KHemorrhageThromboembolismHumansNetherlandsFemaleMaleAgedInternational Normalized RatioAged, 80 and overMiddle AgedTreatment OutcomeCohort StudiesTime FactorsAge FactorsAdministration, Oral

Stichwörter der Autor:innen

acenocoumarolepidemiologyoral anticoagulantsphenprocoumontreatment adherence and compliancetreatment outcome

Substanzen

AnticoagulantsVitamin K

Autor:innen und Institutionen

  • Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.
  • Department of Critical Care Medicine, the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
  • Department of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Department of Quality and Patient Care, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Department of Medicine, Thrombosis and Haemostasis, Leiden University Medical Center, Leiden, the Netherlands.
  • Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands.

ORCID-Profile: Gilda D Zielinski, Qingui Chen, Frederikus A Klok, Suzanne C Cannegieter, Nienke van Rein

Zitieren

APA

Zielinski, G. D., Chen, Q., Kruip, M. J. H. A., Klok, F. A., Cannegieter, S. C., & van Rein, N. (2026). Temporal Trends in Patient Characteristics, Anticoagulation Treatment Quality, and Clinical Outcomes of Individuals Receiving Vitamin K Antagonists in the Netherlands (2014 Until–2022). Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70494

Vancouver

Zielinski GD, Chen Q, Kruip MJHA, Klok FA, Cannegieter SC, van Rein N. Temporal Trends in Patient Characteristics, Anticoagulation Treatment Quality, and Clinical Outcomes of Individuals Receiving Vitamin K Antagonists in the Netherlands (2014 Until–2022). Pharmacoepidemiology and Drug Safety. 2026. doi:10.1002/pds.70494

BibTeX
@article{Zielinski2026,
  author = {Zielinski, Gilda D and Chen, Qingui and Kruip, Marieke J H A and Klok, Frederikus A and Cannegieter, Suzanne C and van Rein, Nienke},
  title = {Temporal Trends in Patient Characteristics, Anticoagulation Treatment Quality, and Clinical Outcomes of Individuals Receiving Vitamin K Antagonists in the Netherlands (2014 Until–2022)},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2026},
  doi = {10.1002/pds.70494}
}
Kostenlos starten →